^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclophosphamide intravenous

    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    Associations

    News

    Trials
    3years
    Identification and Prognostic Value Exploration of Cyclophosphamide (Cytoxan)-Centered Chemotherapy Response-Associated Genes in Breast Cancer. (PubMed, DNA Cell Biol)
    Furthermore, the nomogram model showed that the predicted survival probability is closely related to the actual survival probability. In conclusion, we identified 159 genes potentially correlated with the Cytoxan response of BRCA patients, which had prognostic value in BRCA.
    Journal • BRCA Biomarker
    |
    BRCA (Breast cancer early onset) • PCDHA1 (Protocadherin Alpha 1)
    |
    cyclophosphamide intravenous
    3years
    Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5) (ASH 2021)
    However, ASCT, which includes a standard melphalan conditioning regimen that is associated with systemic toxicity, is not always feasible due to various reasons including advanced age, co-morbidities, and pt frailty...In the cilta-cel arm, pts will undergo apheresis and receive two more 21-d cycles of VRd as bridging therapy; pts will then be administered cilta-cel (target dose: 0.75×10 6 CAR+ viable T cells/kg) 5–7 d after lymphodepletion chemotherapy (intravenous cyclophosphamide 300 mg/m 2 and fludarabine 30 mg/m 2 daily for 3 d) followed by a tx-free observation phase...Results from this study will provide insights into the efficacy and safety of VRd followed by cilta-cel in pts with NDMM. Additionally, VRd tx followed by a single infusion of cilta-cel vs continuous tx with Rd until disease progression may offer pts the benefit of a tx-free period.
    P3 data • Clinical • IO biomarker
    |
    lenalidomide • bortezomib • cyclophosphamide • dexamethasone • melphalan • fludarabine IV • Carvykti (ciltacabtagene autoleucel) • cyclophosphamide intravenous
    3years
    Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. (PubMed, Front Oncol)
    The patients were randomly assigned (1:1) to either 24 weeks of NCT including adriamycin plus cyclophosphamide followed by intravenous docetaxel, or NET involving goserelin acetate and daily tamoxifen. In conclusion, although survival did not differ significantly, more NCT patients might able to avoid ALND, with fewer LNs removed with lower LN positivity. https://clinicaltrials.gov/ct2/show/NCT01622361, identifier NCT01622361.
    Clinical • P3 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    docetaxel • tamoxifen • doxorubicin hydrochloride • goserelin acetate • cyclophosphamide intravenous
    3years
    Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. (PubMed, Lancet Haematol)
    Venetoclax with dose-adjusted EPOCH-R showed an acceptable safety profile at the recommended phase 2 dose and had encouraging preliminary activity in this population at high risk of adverse outcomes, and is worthy of further study. The combination is being investigated in Alliance 051701 (NCT03984448).
    Clinical • P1 data • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 rearrangement
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • etoposide IV • vincristine • prednisone • cyclophosphamide intravenous
    3years
    Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease. (PubMed, Curr Treatm Opt Rheumatol)
    Evidence-based therapeutic recommendations suggest that the best initial approach to treat these patients is an early combination of immunosuppressive drugs including either glucocorticoids and calcineurin inhibitors or a triple therapy adding intravenous cyclophosphamide. Tofacitinib, a Janus kinase inhibitor, could be useful according to recent reports...Combined immunosuppressive treatment should be considered the first-line therapy for patients with anti-MDA5 rapidly progressive interstitial lung disease. Aggressive rescue therapies may be useful in refractory patients.
    Review • Journal
    |
    IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    tofacitinib • cyclophosphamide intravenous
    3years
    Metronomic chemotherapy in elderly non-fit patients with aggressive B-Cell lymphomas. Phase II study Chemioterapia metronomica in pazienti anziani non fit con linfoma a cellule B aggressivo. Studio fase II (clinicaltrialsregister.eu)
    P2, N=60, Ongoing, FONDAZIONE ITALIANA LINFOMI ONLUS
    Clinical • New P2 trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • PIAS4 (Protein Inhibitor Of Activated STAT 4)
    |
    Rituxan (rituximab) • etoposide IV • vinorelbine tartrate • prednisone • cyclophosphamide intravenous
    3years
    RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN PROSTATE CARCINOMA RESISTANT TO STANDARD TREATMENTS TRANSLATE – prostate STUDY ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL TRATTAMENTO STANDARD - studio “TRANSLATE - prostata” (clinicaltrialsregister.eu)
    P2, N=28, Ongoing, AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO
    New P2 trial
    |
    PIAS4 (Protein Inhibitor Of Activated STAT 4)
    |
    Proleukin (aldesleukin) • cyclophosphamide intravenous
    3years
    RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN RENAL CELL CARCINOMA RESISTANT TO STANDARD TREATMENTS TRANSLATE – kidney STUDY ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL TRATTAMENTO STANDARD NEL CARCINOMA RENALE METASTATICO (mRCC) - studio “TRANSLATE - rene” (clinicaltrialsregister.eu)
    P2, N=28, Ongoing, AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO
    New P2 trial
    |
    PIAS4 (Protein Inhibitor Of Activated STAT 4)
    |
    Proleukin (aldesleukin) • cyclophosphamide intravenous
    3years
    RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN METASTATIC COLON-RECTAL CARCINOMA RESISTANT TO STANDARD TREATMENTS TRANSLATE – Colon-rectal STUDY ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL TRATTAMENTO STANDARD - studio “TRANSLATE – colon-retto” (clinicaltrialsregister.eu)
    P2, N=28, Ongoing, AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO
    New P2 trial
    |
    PIAS4 (Protein Inhibitor Of Activated STAT 4)
    |
    Proleukin (aldesleukin) • cyclophosphamide intravenous
    over3years
    Primary central nervous system lymphoma in a patient with neuropsychiatric systemic lupus erythematosus receiving mycophenolate mofetil: A case report and literature review. (PubMed, Mod Rheumatol Case Rep)
    She was diagnosed as having neuropsychiatric lupus and lupus nephritis and received remission induction therapy with high-dose corticosteroid and intravenous cyclophosphamide...Remission induction therapy with rituximab, high-dose methotrexate, procarbazine, and vincristine was administered, and she achieved remission. Previous reports suggest that use of MMF is associated with primary central nervous system (CNS) lymphoma (PCNSL) in patients with lupus nephritis or other autoimmune diseases or in post-transplant patients. Our observation that PCNSL occurred after CNS involvement of SLE suggests that EBV and CNS inflammation arising from SLE might have contributed to the development of PCNSL.
    Clinical • Review • Journal
    |
    IL6 (Interleukin 6)
    |
    Rituxan (rituximab) • methotrexate • vincristine • Matulane (procarbazine hydrochloride) • cyclophosphamide intravenous • methotrexate IV
    over3years
    RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN BREAST CARCINOMA RESISTANT TO STANDARD TREATMENTS ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL TRATTAMENTO STANDARD - studio “TRANSLATE - breast” (clinicaltrialsregister.eu)
    P2, N=28, Ongoing, AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO
    New P2 trial
    |
    PIAS4 (Protein Inhibitor Of Activated STAT 4)
    |
    Proleukin (aldesleukin) • cyclophosphamide intravenous
    over3years
    Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa (clinicaltrials.gov)
    P2; Trial completion date: Mar 2020 --> Mar 2022
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous
    over3years
    SPiReL: DPX-Survivac and Checkpoint Inhibitor in DLBCL (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, Sunnybrook Health Sciences Centre | Trial completion date: Apr 2022 --> Oct 2022 | Trial primary completion date: Apr 2021 --> Oct 2021
    Clinical • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    BIRC5 (Baculoviral IAP repeat containing 5)
    |
    BIRC5 expression
    |
    Keytruda (pembrolizumab) • maveropepimut-S (MVP-S) • cyclophosphamide intravenous
    over3years
    Study of combination of metronomic chemotherapy and reactivator of immune response in inflammatory breast cancer spread to the chest wall. Studio di combinazione di chemioterapia metronomica e riattivatore della risposta immunitaria nei tumori mammari infiammatori con interessamento della parete toracica. (clinicaltrialsregister.eu)
    P2, N=46, Ongoing, ISTITUTO EUROPEO DI ONCOLOGIA
    Clinical • New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    HER-2 positive • HR positive
    |
    Keytruda (pembrolizumab) • cyclophosphamide • cyclophosphamide intravenous
    over3years
    Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2021 --> Aug 2023 | Trial primary completion date: Aug 2021 --> Aug 2023
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • IKZF1 mutation • MLL mutation
    |
    melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous
    over3years
    Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies (clinicaltrials.gov)
    P2, N=72, Recruiting, Sidney Kimmel Cancer Center at Thomas Jefferson University | Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Jul 2021 --> Jul 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    Chr del(5q)
    |
    fludarabine IV • thiotepa • cyclophosphamide intravenous
    over3years
    Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301) (clinicaltrials.gov)
    P3, N=346, Completed, National Heart, Lung, and Blood Institute (NHLBI) | Active, not recruiting --> Completed | Trial completion date: Sep 2021 --> Oct 2020 | Trial primary completion date: Aug 2021 --> Oct 2020
    Clinical • Trial completion • Trial completion date • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    cyclophosphamide intravenous
    over3years
    ATG Plus PTCy vs ATG for CGVHD Prophylaxis (clinicaltrials.gov)
    P2, N=80, Recruiting, McMaster University | Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Jun 2021 --> Oct 2024
    Clinical • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    cyclophosphamide intravenous
    over3years
    Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=10, Terminated, University of Southern California | Trial completion date: Jul 2021 --> Mar 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2020 --> Mar 2021; Insufficient accrual
    Clinical • Trial completion date • Trial termination • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 overexpression
    |
    Herceptin (trastuzumab) • lapatinib • capecitabine • cyclophosphamide • cyclophosphamide intravenous
    over3years
    Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=15, Recruiting, Fred Hutchinson Cancer Research Center | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin)
    |
    MSLN expression
    |
    fludarabine IV • cyclophosphamide intravenous
    over3years
    Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P2, N=68, Recruiting, Fred Hutchinson Cancer Research Center | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
    Clinical • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    methotrexate • fludarabine IV • thiotepa • busulfan • cyclophosphamide intravenous • methotrexate IV
    over3years
    Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer (clinicaltrials.gov)
    P2, N=185, Not yet recruiting, Baylor Breast Care Center
    Clinical • New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HR positive + HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide intravenous
    over3years
    Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma (clinicaltrials.gov)
    P2, N=94, Completed, St. Jude Children's Research Hospital | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 expression
    |
    Rituxan (rituximab) • cytarabine • etoposide IV • methotrexate • vincristine • clofarabine • mitoxantrone • Oncaspar liquid (pegaspargase) • Vumon (teniposide) • mercaptopurine • vinblastine • Proleukin (aldesleukin) • cyclophosphamide intravenous
    over3years
    Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Xinqiao Hospital of Chongqing
    Clinical • New P1 trial • CAR T-Cell Therapy
    |
    CD33 (CD33 Molecule)
    |
    CD33 expression
    |
    fludarabine IV • cyclophosphamide intravenous
    over3years
    Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas (clinicaltrials.gov)
    P=N/A, N=19, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Aug 2021 --> Dec 2021 | Trial primary completion date: Aug 2021 --> Dec 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    MSLN (Mesothelin)
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • cyclophosphamide intravenous
    over3years
    GITMO-PHYLOS: Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies (clinicaltrials.gov)
    P2, N=78, Recruiting, Gruppo Italiano Trapianto di Midollo Osseo | Trial completion date: Dec 2021 --> Dec 2022
    Clinical • Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    cyclophosphamide intravenous
    over3years
    CARTITUDE-5: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (clinicaltrials.gov)
    P3, N=650, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • CAR T-Cell Therapy • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10)
    |
    lenalidomide • bortezomib • dexamethasone • fludarabine IV • Carvykti (ciltacabtagene autoleucel) • cyclophosphamide intravenous
    over3years
    Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd) (clinicaltrials.gov)
    P1/2, N=63, Active, not recruiting, European Myeloma Network | Trial completion date: Apr 2021 --> Dec 2021
    Clinical • Trial completion date
    |
    CRP (C-reactive protein)
    |
    cyclophosphamide • carfilzomib • cyclophosphamide intravenous
    over3years
    Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (clinicaltrials.gov)
    P1/2, N=36, Active, not recruiting, European Myeloma Network | Trial completion date: Jun 2021 --> Dec 2021
    Clinical • Trial completion date
    |
    CRP (C-reactive protein)
    |
    cyclophosphamide • carfilzomib • cyclophosphamide intravenous
    over3years
    BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma (clinicaltrials.gov)
    P1, N=18, Suspended, Fred Hutchinson Cancer Research Center | Trial primary completion date: Jul 2021 --> Apr 2022
    Clinical • Trial primary completion date • Combination therapy • CAR T-Cell Therapy
    |
    SDC1 (Syndecan 1)
    |
    fludarabine IV • crenigacestat (LY3039478) • cyclophosphamide intravenous
    over3years
    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma (clinicaltrials.gov)
    P2, N=12, Recruiting, Masonic Cancer Center, University of Minnesota | Trial primary completion date: Jul 2021 --> Jul 2022
    Clinical • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    carboplatin • etoposide IV • melphalan • thiotepa • cyclophosphamide intravenous
    over3years
    Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (clinicaltrials.gov)
    P2/3, N=374, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Clinical • Trial suspension
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • etoposide IV • vincristine • cyclophosphamide intravenous
    over3years
    CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies (clinicaltrials.gov)
    P1, N=25, Not yet recruiting, Mayo Clinic | Initiation date: Jun 2021 --> Oct 2021
    Trial initiation date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • PLCG2 (Phospholipase C Gamma 2)
    |
    fludarabine IV • cyclophosphamide intravenous
    over3years
    Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) (clinicaltrials.gov)
    P3, N=590, Not yet recruiting, Fudan University | Trial completion date: Sep 2026 --> Sep 2030 | Trial primary completion date: Sep 2023 --> Sep 2027
    Clinical • Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    cisplatin • carboplatin • etoposide IV • cyclophosphamide intravenous
    over3years
    REPROGRAM-01: Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=49, Active, not recruiting, Centre Hospitalier Universitaire de Besancon | Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Jan 2022 --> Apr 2022
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    capecitabine • Stivarga (regorafenib) • aspirin • cyclophosphamide intravenous
    over3years
    The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer (clinicaltrials.gov)
    P1, N=10, Recruiting, Shanghai 6th People's Hospital | Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Jan 2021 --> Jan 2023
    Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    fludarabine IV • anti- MESO CAR-T cells • cyclophosphamide intravenous
    over3years
    BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma (clinicaltrials.gov)
    P1, N=18, Suspended, Fred Hutchinson Cancer Research Center | Trial completion date: Jul 2034 --> Apr 2022 | Recruiting --> Suspended
    Clinical • Trial completion date • Trial suspension • Combination therapy • CAR T-Cell Therapy
    |
    SDC1 (Syndecan 1)
    |
    fludarabine IV • crenigacestat (LY3039478) • cyclophosphamide intravenous
    over3years
    Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P2, N=30, Recruiting, Roswell Park Cancer Institute | Trial completion date: Jul 2022 --> Aug 2023 | Trial primary completion date: Jul 2021 --> Aug 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    sirolimus • fludarabine IV • captisol-enabled melphalan • cyclophosphamide intravenous
    over3years
    Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS (clinicaltrials.gov)
    P2, N=25, Recruiting, New York Medical College | Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Jun 2022
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD33 (CD33 Molecule)
    |
    Mylotarg (gemtuzumab ozogamicin) • busulfan • cyclophosphamide intravenous
    over3years
    In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies (clinicaltrials.gov)
    P1, N=24, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
    Preclinical • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide intravenous
    over3years
    Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma (clinicaltrials.gov)
    P=N/A, N=19, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Jul 2021 --> Jul 2023
    Clinical • Trial completion date
    |
    IFNG (Interferon, gamma)
    |
    Proleukin (aldesleukin) • cyclophosphamide intravenous
    over3years
    LYTPET: Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, British Columbia Cancer Agency | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    carboplatin • Rituxan (rituximab) • doxorubicin hydrochloride • ifosfamide • etoposide IV • vincristine • Zuplenz (ondansetron oral dispersible film) • cyclophosphamide intravenous